within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H04A_GlycogenolyticHormones.H04AA02_Dasiglucagon;

model Dasiglucagon
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.438888888888889e-05,
    adminDuration = 600,
    adminMass = 0.6 / 1000000,
    adminCount = 1,
    Vd = 0.00011999999999999999,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dasiglucagon</td></tr><tr><td>ATC code:</td><td>H04AA02</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>0.6</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.12</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.74</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dasiglucagon is a glucagon analog used for the treatment of severe hypoglycemia in patients with diabetes mellitus. It is a stable formulation of glucagon, suitable for subcutaneous administration, and is approved for use in both adults and children aged 6 and above for emergency treatment of severe hypoglycemic episodes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects following a single subcutaneous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.H.H04AA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dasiglucagon;
